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Abstract
Background: In the United States, HIV-related kidney disease disproportionately affects individuals of African descent;
however, there are few estimates of kidney disease prevalence in Africa. We evaluated the prevalence of kidney disease
among HIV-infected and uninfected Rwandan women.
Methods: The Rwandan Women’s Interassociation Study and Assessment prospectively enrolled 936 women. Associations
with estimated glomerular filtration rate (eGFR),60 mL/min/1.73 m
2 and proteinuria were assessed in separate logistic
regression models.
Results: Among 891 non-pregnant women with available data, 2.4% had an eGFR,60 mL/min/1.73 m
2 (calculated by the
Modification of Diet in Renal Disease equation, MDRD eGFR) and 8.7% had proteinuria $1+. The prevalence of decreased
eGFR varied markedly depending on the estimating method used, with the highest prevalence by Cockcroft-Gault.
Regardless of the method used to estimate GFR, the proportion with decreased eGFR or proteinuria did not differ
significantly between HIV-infected and -uninfected women in unadjusted analysis. After adjusting for age and blood
pressure, HIV infection was associated with significantly higher odds of decreased MDRD eGFR but not proteinuria.
Conclusion: In a well-characterized cohort of Rwandan women, HIV infection was associated with decreased MDRD eGFR.
The prevalence of decreased eGFR among HIV-infected women in our study was lower than that previously reported in
African-Americans and in other Central and East African HIV populations, although there was substantial variability
depending on the equation used to estimate GFR. Future studies are needed to optimize GFR estimates and to determine
the impact of antiretroviral therapy on kidney disease in this population.
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Introduction
In 2008 there were an estimated 33.4 million individuals living
with human immunodeficiency virus (HIV) infection. Sub-
Saharan Africa bears the greatest burden of disease, with two-
thirds of all HIV-infected individuals [1]. Strong genetic
susceptibility to chronic kidney disease (CKD) and end-stage
renal disease (ESRD) has been observed in African-Americans [2–
4], and the risk of ESRD is as much as 30-fold higher among HIV-
infected Americans of African compared to European descent
[5,6]. Epidemiological data on CKD in sub-Saharan Africa are
scarce, and available data demonstrate substantial variability in
CKD prevalence across different African HIV populations [7–10].
The regional prevalence of CKD may influence the approach to
screening and monitoring of HIV-infected individuals initiating
antiretroviral therapy (ART). In particular, most nucleoside/
nucleotide reverse transcriptase inhibitors (NRTI) are eliminated
by the kidney and may require dose adjustment in individuals with
decreased glomerular filtration rate (GFR), while agents such as
the NRTI tenofovir and the protease inhibitor indinavir have
known nephrotoxic potential and may require more intensive
monitoring in individuals with pre-existing CKD [11].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18352We examined enrollment data from the Rwandan Women’s
Interassociation Study and Assessment (RWISA), an observational
cohort study of HIV-infected and uninfected Rwandan women, to
determine the prevalence of kidney disease in this previously
unstudied population.
Methods
RWISAisanobservational prospectivecohortstudyinvestigating
the effectiveness and toxicity of ART in HIV-infected Rwandan
women. Nine hundred thirty-six women (710 HIV infected and 226
HIV uninfected) enrolled in 2005. Written informed consent was
obtained in accordance with protocols approved by the Rwandan
National Ethics Committee and the Institutional Review Board of
Montefiore Medical Center, Bronx NY, USA. Inclusion criteria for
RWISA included age $25 years, willingness to be HIV tested and
return for follow-up, and presence in Rwanda in 1994. HIV-
infected women were also naı ¨ve to ART at entry, except for exposure
to single-dose nevirapine. At study entry, participants provided
demographic information and medical and psychosocial history.
Physical examinations and bioimpedance analysis were performed
by trained research nurses. Specimens were obtained at enrollment
for CD4 cell count, serum creatinine and albumin, urine pregnancy
test, and dipstick urinalysis.
Blood pressure was recorded as the average of two sphygmo-
manometry measures. Total body fat and fat free mass were
calculated using established techniques [12]. Spot urine samples
were tested for the presence of protein and blood using the
AimStick 10-SG Urine Reagent Strips (Germaine Laboratories,
San Antonio, Texas USA) or the Humantest Combina 10 M
(Wiesbaden, Belgium). Proteinuria was defined as the presence of
$+1 protein on a single urine specimen obtained at the enrollment
visit. To minimize artifact from menses or cystitis, specimens with
significant hematuria (medium or large blood) were excluded
(n=21). Serum creatinine was measured by Jaffe reaction
(Beckman Instrument Inc., Brea, CA, USA). Estimated glomerular
filtration rate (eGFR) was calculated from a single serum
creatinine value obtained at the enrollment visit, using the 4-
variable Modification of Diet in Renal Disease (MDRD), CKD
Epidemiology Collaboration (CKD-EPI), and Cockcroft-Gault
equations [13–15]. Primary analyses were based on MDRD
eGFR,60 mL/min/1.73 m
2 to allow comparison with previous
observational studies and with current guidelines for the diagnosis
of CKD [11]. We also considered an eGFR cutoff of 50 mL/min/
1.73 m
2, the level at which dose adjustment is recommended for
most NRTI. Finally, we considered the impact of eliminating the
adjustment factor for black race in the MDRD and CKD-EPI
equations, based on evidence that this adjustment may not
Table 1. Clinical and demographic variables stratified by HIV status.
HIV-infected
(n=677)
Median (IQR)
Or n (%)
HIV-uninfected
(n=214)
Median (IQR)
Or n (%) p-value
b
Age (years) 34 (30–39) 43 (34–50) ,0.01
Self-reported diabetes mellitus 3 (0.5%)
(n=671)
a
1 (0.5%)
(n=204)
a
1.00
Self-reported hypertension 32 (4.8%)
(n=671)
a
17 (8.3%)
(n=204)
a
0.06
Weight (kg) 52 (46–58) 52 (46–61) 0.23
Body mass index (kg/m
2) 20.9 (19.0–23.3) 20.5 (18.5–23.3) 0.23
Lean body mass (kg) 40.3 (37.3–42.9)
(n=570)
a
41.4 (38.6–44.7)
(n=204)
a
,0.01
Total body fat (kg) 11.8 (7.8–16.5)
(n=568)
a
10.5 (6.6–18.1)
(n=204)
a
0.47
Systolic blood pressure (mmHg) 119 (110–122.5) 120 (110–125)
(n=213)
a
0.019
Diastolic blood pressure (mmHg) 70 (65–78) 72 (68.5–80)
(n=212)
a
,0.01
CD4 cell count (cells/ml) 256 (163–360)
(n=675)
a
---- ----
WHO Stage 4 HIV (with weight loss) 281 (41.5%) ---- ----
Serum albumin (g/dL) 3.5 (3.1–3.8)
(n=659)
a
4.0 (3.6–4.2)
(n=209)
a
,0.01
Serum creatinine (mg/dL) 0.92 (0.82–1.02)
(n=659)
a
0.85 (0.75–0.96)
(n=206)
a
,0.01
eGFR (mL/min/1.73 m
2) 90.0 (78.4–103.9) 94.5 (82.4–109.3) ,0.01
eGFR,60 mL/min/1.73 m
2 18 (2.7%) 3 (1.5%) 0.44
Proteinuria (urine protein $1+) 55 (9.0%)
(n=614)
a
9 (7.2%)
(n=125)
a
0.60
aFor variables with missing data, the number of women with available data is reported.
bFisher’s Exact test for categorical and Wilcoxon two-sample test for continuous variables.
IQR: interquartile range; WHO, World Health Organization Clinical Stage of HIV; eGFR: estimated glomerular filtration rate by 4-variable Modification of Diet in Renal
Disease (MDRD) equation.
doi:10.1371/journal.pone.0018352.t001
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(n=16) were excluded from the current analysis due to physiologic
changes in GFR and urinary protein excretion during pregnancy.
To reduce the impact of outliers on the evaluation of associations
between body composition and CKD prevalence, extreme weight
outliers with body mass index (BMI)$30 were also excluded
(n=29).
Statistical analysis
Continuous and categorical variables were compared between
groups using Student’s T-test or Wilcoxon rank sum test and
Pearson’s Chi-Square or Fisher’s Exact test as appropriate.
Stepwise multivariable logistic regression evaluated associations
with proteinuria and eGFR,60 mL/min/1.73 m
2 among the
cohort overall and in HIV-infected women in separate models.
Variables tested for inclusion in the models included HIV status,
age, serum albumin, BMI, lean body mass, total body fat, and
systolic and diastolic blood pressure. CD4 count was assessed in
HIV-infected women. As the primary predictor of interest, HIV
serostatus was forced into multivariate models, while other
covariates with p-value,0.05 were retained in the final models
using backwards selection.
Results
Eight hundred ninety-one non-pregnant women were included
in the current analysis (677 HIV infected and 214 uninfected),
including 865 with data available for estimation of GFR and 739
with eligible urine specimens for assessment of proteinuria
(Table 1). HIV-infected women were younger than HIV-
uninfected women (median age 34 versus 43 years, p,0.01). Self-
reported diabetes and hypertension were rare, with a trend
towards more hypertension among HIV-uninfected women.
Median weight was 52 kg and median BMI was 20.9 kg/m
2,
with no significant difference between HIV-infected and HIV-
uninfected women.
Overall, 21 women (2.4%) had an MDRD eGFR,60 mL/
min/1.73 m
2 and 64 women (8.7%) had proteinuria $1+
(Table 1). The prevalence of decreased eGFR varied substantially
depending on the estimating method used, with a nearly 10-fold
higher prevalence of eGFR,60 mL/min/1.73 m
2 when the
Cockcroft-Gault equation was employed (Table 2). Similar
patterns were observed for eGFR,50 mL/min/1.73 m
2 and
when the adjustment factor for black race was eliminated from
the MDRD and CKD-EPI equations (Table 2). There was only
one participant with both proteinuria and decreased MDRD
eGFR, a 50-year-old HIV-infected woman with a CD4 cell count
of 249 cells/m
3. Although there were 20 women with both
proteinuria and Cockcroft-Gault eGFR,60 mL/min, there was
no significant association between proteinuria and decreased
eGFR regardless of the method used to estimate GFR (data not
shown).
The proportion of women with decreased eGFR or proteinuria
did not differ significantly between HIV-infected and -uninfected
women, regardless of the equation used to calculate eGFR.
However, after adjusting for age, blood pressure, body composi-
Table 3. Univariate and multivariate associations with kidney disease in all participants.
eGFR,60
a
Unadjusted OR Adjusted OR
Proteinuria
b
Unadjusted OR Adjusted OR
c
HIV Status (1 for +, 0 for 2) 1.90 (0.55–6.52) 8.91 (1.57–50.49)* 1.27 (0.61–2.64) 1.66 (0.67–4.12)
Age (years) 1.63 (1.07–2.50)* 2.20 (1.31–3.68)** 1.33 (1.00–1.77)* 1.33 (0.96–1.86)
Body mass index (per kg/m
2) 1.10 (0.74–1.63) 0.87 (0.68–1.11)
Lean body mass (per kg) 1.34 (0.87–2.06) 0.90 (0.67–1.21)
Total body fat (per kg) 1.17 (0.86–1.60) 0.88 (0.71–1.08)
Systolic blood pressure 1.24 (0.94–1.65) 0.99 (0.79–1.25)
Diastolic blood pressure 1.49 (1.01–2.21)* 1.68 (1.08–2.63)* 1.36 (1.02–1.82)* 1.42 (1.05–1.91)*
Serum albumin (per g/dL) 0.91 (0.48–1.70) 0.69 (0.48–0.99)* 0.64 (0.43–0.94)*
Serum creatinine (per mg/dL) 1.51 (0.39–5.86)
Note: * for p,0.05, ** for p,0.01 and *** for p,0.001.
aEstimated glomerular filtration rate calculated using the 4-variable Modification of Diet in Renal Disease Equation.
bUrine protein 1+ or greater.
cBackwards stepwise selection with a p=0.05 to remain and HIV serostatus forced in.
doi:10.1371/journal.pone.0018352.t003
Table 2. Prevalence of decreased glomerular filtration rate
stratified by HIV status and estimating equation.
HIV-infected
(n=659)
n( % )
HIV-
uninfected
(n=206)
n (%) p-value
eGFR,60 mL/min/1.73 m
2
MDRD 18 (2.7%) 3 (1.5%) 0.44
MDRD unadjusted for race 97 (14.7%) 22 (10.7%) 0.16
CKD-EPI 16 (2.4%) 2 (1.0%) 0.27
CKD-EPI unadjusted for race 52 (7.9) 14 (6.8%) 0.66
Cockcroft-Gault (mL/min) 166 (25.2%) 50 (24.3%) 0.79
eGFR,50 mL/min/1.73 m
2
MDRD 4 (0.6%) 0 (0.0%) 0.58
MDRD unadjusted for race 20 (3.0%) 3 (1.5%) 0.32
CKD-EPI 4 (0.6%) 0 (0.0%) 0.58
CKD-EPI unadjusted for race 10 (1.5%) 1 (0.5%) 0.47
Cockcroft-Gault (mL/min) 60 (9.1%) 20 (9.7%) 0.79
eGFR: estimated glomerular filtration rate; MDRD: 4-variable Modification of
Diet in Renal Disease equation; CKD-EPI: Chronic Kidney Disease Epidemiology
Consortium equation.
doi:10.1371/journal.pone.0018352.t002
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dently associated with decreased MDRD eGFR (adjusted OR 8.9,
95% CI 1.6–50.5), but not with the presence of proteinuria
(adjusted OR 1.7; 95% CI 0.7–4.1). Higher diastolic blood
pressure was also independently associated both with decreased
MDRD eGFR and with proteinuria, while older age was
associated with decreased MDRD eGFR in the overall cohort.
Among HIV-infected women, older age remained a predictor of
decreased MDRD eGFR, while higher diastolic blood pressure
and lower serum albumin were independently associated with the
presence of proteinuria (Table 4). Although the proportion with
either proteinuria or decreased MDRD eGFR was highest among
HIV-infected women with CD4 cell count ,200 (15% versus 9%
in HIV-infected women with CD4 cell count $200, p=0.05),
CD4 cell count was not significantly associated with decreased
MDRD eGFR or with proteinuria in adjusted analyses. There was
no association of decreased MDRD eGFR or proteinuria with
measures of body composition, including BMI, lean body mass, or
total body fat.
Discussion
In this well-characterized cohort of Rwandan women, HIV
infection was independently associated with decreased MDRD
eGFR in adjusted, but not unadjusted, analysis. The prevalence of
decreased MDRD eGFR among HIV-infected women in this
study was lower than that observed in previous studies in HIV-
infected African-Americans [5,18] and in other Central and East
African populations [7,9,10,19], while the prevalence of protein-
uria was similar to that previously reported among HIV-infected
individuals in Kenya and South Africa [7,20]. Consistent with
other recent reports from sub-Saharan Africa, the prevalence of
decreased eGFR varied substantially depending on the estimating
method used [16,17].
Both HIV-associated nephropathy (HIVAN) and HIV-related
ESRD are known to disproportionately affect African-Americans
[5,6]. With the recent discovery of a locus on chromosome 22 that
is associated with genetic susceptibility to HIVAN and other forms
of CKD and ESRD among African-Americans [2–4], there is
increasing concern about the burden of HIV-related CKD in sub-
Saharan Africa [21]. Available data suggest substantial regional
variability in the prevalence of HIV-related CKD. The highest
burden has been observed in West Africa, consistent with the
predominant ancestry of the genetically susceptible African-
American population [8].
With expanding access to ART across Africa, including the use
of agents with nephrotoxic potential, the local prevalence of HIV-
related CKD may be a valuable determinant of the need to screen
and monitor for CKD in individuals initiating ART. The
Development of ART in Africa Trial (DART) randomized adults
initiating ART in Uganda and Zimbabwe to routine laboratory
monitoring or clinically driven monitoring, with laboratory data
collected for all subjects but only made available to providers in
the clinically driven monitoring arm when requested based on
clinical signs and symptoms [22]. There was no significant
difference in renal adverse events between the two monitoring
Table 4. Univariate and multivariate associations with kidney disease in HIV-infected participants.
eGFR,60
a
Unadjusted OR Adjusted OR
Proteinuria
b
Unadjusted OR Adjusted OR
c
Age (years) 2.20 (1.27–3.81)** 2.20 (1.27–3.81)** 1.38 (0.95–2.00)
Body mass index (per kg/m
2) 0.85 (0.54–1.33) 0.98 (0.75–1.27)
Lean body mass (per kg) 1.22 (0.75–1.98) 0.96 (0.70–1.33)
Total body fat (per kg) 1.02 (0.71–1.47) 0.98 (0.78–1.22)
Systolic blood pressure 0.89 (0.57–1.39) 1.02 (0.77–1.33)
Diastolic blood pressure 1.08 (0.58–2.03) 1.88 (1.28–2.76)** 1.95 (1.33–2.88)***
CD4 cell count (per 100 cells/ml) 0.91 (0.67–1.23) 0.82 (0.67–0.99)*
Serum albumin (per g/dL) 1.00 (0.50–1.99) 0.60 (0.40–0.88)** 0.56 (0.37–0.83)**
Serum creatinine (per mg/dL) 1.22 (0.27–5.44)
Note: * for p,0.05, ** for p,0.01 and *** for p,0.001.
aEstimated glomerular filtration rate calculated using the 4-variable Modification of Diet in Renal Disease Equation.
bUrine protein 1+ or greater.
cBackwards stepwise selection with a p=0.05 to remain.
doi:10.1371/journal.pone.0018352.t004
Table 5. Comparison of RWISA participants to the MDRD, CKD-EPI, and Cockcroft-Gault study populations.
Mean Weight Mean BSA Mean BMI Mean Age Female Black race
MDRD 80 kg 1.91 m
2 27 kg/m
2 51 years 40% ,12%
CKD-EPI 82 kg 1.93 m
2 28 kg/m
2 47 years 43% 32%
Cockcroft-Gault 72 kg NA NA Range 18–92 years NA NA
RWISA 53 kg 1.52 m
2 21 kg/m
2 37 Years 100% 100%
MDRD: Modification of Diet in Renal Disease Equation; CKD-EPI: Chronic Kidney Disease Epidemiology Consortium Equation; BSA: body surface area; BMI: body mass
index.
doi:10.1371/journal.pone.0018352.t005
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guidelines, which do not advocate universal laboratory screening
for CKD prior to ART initiation in resource-limited settings [23].
Nonetheless, it is not known whether a clinically driven screening
and monitoring strategy can be safely adopted throughout Africa,
highlighting the need to investigate the prevalence of CKD
and other relevant comorbidities in previously understudied
populations.
The relatively low prevalence of decreased MDRD eGFR
observed in Rwandan women would support the safety of WHO
recommendations to forgo universal pre-ART CKD screening in
this population [23]. In contrast, the Cockcroft-Gault equation
identified evidence of decreased kidney function in more than one-
quarter of HIV-infected women, and nearly 10% would have
required dose reduction of NRTI’s including tenofovir. This
striking difference in the performance of different GFR estimates
has been reported in other African populations [7,10,24,25], and
has been attributed to differences in body composition compared
to the North American populations in which the equations were
derived (Table 5). Our primary analyses were based on MDRD
eGFR to allow comparison with previous observational studies
and current guidelines for the diagnosis of CKD [11]; however,
future studies are needed to validate or optimize GFR estimates
for use in African populations. With increasing use of tenofovir as
first-line therapy, these studies may influence guidelines for CKD
screening and monitoring in patients initiating ART in resource-
poor settings.
Prior studies in Central and East Africa have reported a higher
prevalence of decreased MDRD eGFR among ART-naı ¨ve
individuals than we observed in the current study [7,10,19].
Several of those studies included patients with more advanced
HIV disease, as evidenced by lower CD4 cell count or
symptomatic disease [9,10,24]. In contrast, the prevalence of
proteinuria observed in our population was similar to that
reported in studies from Kenya and South Africa [7,20]. We
have previously reported increased mortality associated with
proteinuria among HIV-infected women in the United States
[26–28], and future studies should investigate whether proteinuria
is also a predictor of adverse outcomes among HIV-infected
individuals in Africa.
In addition to the lack of validated GFR estimates for use in an
African population, this study has several other important
limitations. RWISA enrolled a cohort of HIV-infected women
with a broad range of CD4 count and clinical disease, and
prevalence estimates derived from this study may not be
generalizable to Rwandan men and older women or to individuals
with very advanced HIV disease. In addition, we were limited by
the use of a single serum creatinine and a single urinalysis to
identify women with kidney disease. Guidelines for CKD diagnosis
require documentation of decreased eGFR or proteinuria for at
least 3 months [11], and application of these guidelines would
likely result in a lower estimated prevalence of CKD than we have
reported. Nonetheless, repeated measures are rarely feasible prior
to ART initiation in resource-poor settings, and future guidelines
will likely rely on at most a single laboratory result to drive
decision-making in this setting.
In a well-characterized cohort of Rwandan women, HIV
infection was associated with decreased MDRD eGFR but not
with the presence of proteinuria. The prevalence of decreased
eGFR among HIV-infected women was lower than that reported
in previous studies in Central and East Africa, supporting the
WHO’s recommended strategy of targeted pre-ART screening for
CKD in this setting [23]. Proteinuria was observed more
commonly in our population. Although there was no correlation
between the presence of proteinuria and decreased eGFR at the
time of enrollment, future studies should investigate whether
proteinuria is a useful non-invasive marker of risk for nephrotox-
icity in African women initiating ART. Importantly, this study also
highlights the need for future research to validate and optimize
GFR estimates for use in African populations.
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